New Phase III Data Analysis for BiovaxID, Personalized Lymphoma Vaccine, to Be Presented at ASH Annual Meeting
TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Nov 15, 2010 - Biovest International, Inc. (OTCQB: BVTI) today announced that BiovaxID®, Biovest's personalized lymphoma vaccine, will be featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Monday, December 6th in Orlando, Florida.
Stephen J. Schuster, M.D., Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, will deliver the BiovaxID presentation titled, “Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration in Follicular Lymphoma Patients.”
The abstract can be accessed at the ASH website by visiting: http://ash.confex.com/ash/2010/webprogram/Paper34600.html
Note to editors: Pursuant to ASH policy, coverage of information that goes beyond that which is contained in the abstract is embargoed until 11:00 a.m. (EST) on Monday, December 6th. At that time, Biovest will provide additional analysis, commentary and updated information.
Phase III Study Results Presentation at ASH
December 6, 2010 at 11:00 a.m. (EST)
County Convention Center, Orlando, Room #311 EFGH
About Biovest International, Inc.
Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin's lymphoma and mantle cell lymphoma.
Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQB™ Market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPIQ”).
For further information, please visit: http://www.biovest.com
Special Note: Biovest expects to soon launch its new website.
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to statements about BiovaxID®, AutovaxID™, events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Contact: Biovest International, Inc.
Douglas Calder, Director of Investor Relations & Public Relations
Posted: November 2010